P1943-Nb2cL - aTyr Pharma
Latest Information Update: 27 Apr 2026
At a glance
- Originator aTyr Pharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Neuropilin-2 stimulants; PLXNA1 protein stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer